Pharmaceuticals, Biotechnology and Life Sciences
– New preclinical data show anti-tumor response to Company’s eIF4E inhibitors in ER+ breast cancer – – In vivo proof-of-concept…
– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. – – Approximately 16,000 patients 12 years of age…
Severe vaso-occlusive events were eliminated for 94% (30/32) of evaluable patients and all VOEs were eliminated for 88% (28/32) of…
– Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone –…
– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people…
CHICAGO–(BUSINESS WIRE)–The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per…
BostonGene’s innovative solutions and deep expertise in AI-based molecular and immune profiling recognized as a leader in diagnosis and imaging,…
Site is Unique in its Size and Full Dedication to Medical and Surgical Treatment of Retinal Diseases CINCINNATI–(BUSINESS WIRE)–EyeCare Partners…
– Study will evaluate the potential of triple combination of NKT2152, atezolizumab and bevacizumab versus atezolizumab and bevacizumab alone, in…
This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration…